Using Sirolimus for Posttransplant Management and Reduction of Tuberous Sclerosis Complex Progression in a Patient with End Stage Renal Disease Caused by Tuberous Sclerosis Complex.
10.4285/jkstn.2014.28.4.241
- Author:
Kang Hun LEE
1
;
Han Sae KIM
;
Sung Han YUN
;
Jin Ho LEE
;
Joon Seok OH
;
Seung Min KIM
;
Yong Hun SIN
;
Joong Kyung KIM
Author Information
1. Division of Nephrology, Department of Internal Medicine, Bong Seng Memorial Hospital, Busan, Korea. j-seok@hanmail.net
- Publication Type:Case Report
- Keywords:
Tuberous sclerosis complex;
Kidney transplantation;
Sirolimus
- MeSH:
Adolescent;
Angiofibroma;
Angiomyolipoma;
Astrocytoma;
Brain;
Hamartoma;
Hand;
Humans;
Immunosuppression;
Kidney Failure, Chronic*;
Kidney Transplantation;
Male;
Rhabdomyoma;
Sirolimus*;
Skin;
Tuberous Sclerosis*
- From:The Journal of the Korean Society for Transplantation
2014;28(4):241-245
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Tuberous sclerosis complex (TSC) is a neurocutaneous disease characterized by the formation of hamartomas in multiple organs. TSC can show lesions including facial angiofibroma, shagreen patch on the skin, cortical tuber, subependymal nodule, astrocytoma in the brain, cardiac rhabdomyoma, and renal angiomyolipoma. In particular, renal angiomyolipoma may be a cause of end-stage renal disease (ESRD). On the other hand, sirolimus has regulatory effects on cellular growth and proliferation via its inhibitory effect on a protein, mammalian target of rapamycin. We report on a case of an 18-year-old male who underwent renal transplantation due to ESRD induced by TSC. Sirolimus played a role in successful treatment of TSC and effective immunosuppression for transplantation.
